Since the start of the outbreak; researchers, pharma firms, governments all over the world are scrambling to find a treatment. From herbal medications to repurposing older drugs as potential COVID-19 therapies, anything which could possibly save lives is being tested and of course the hunt for a vaccine is on. There are 16 vaccine candidates in clinical evaluations and 125 candidates in preclinical evaluation around the world. (As of June 24, 2020. Source: WHO)
Developing a vaccine is a time-consuming process. Vaccines, on an average, take 10 years to develop. The fastest vaccine ever developed till date was approved for the mumps in 1967, took four years. The latest vaccine developed for an epidemic, Ebola vaccine, also took five years,was approved in 2019. Both the vaccines were developed by Merck.
Though the vaccine is touted as the fastest to develop, developing a vaccine that is safe, effective and producing it in large quantities that the world needs to fight a pandemic is a surmountable challenge. It is interesting to note that there is still no licensed vaccine for an earlier Coronavirus, Severe acute respiratory syndrome (SARS). Studies showed that some preliminary SARS vaccines enhanced the disease in model experiments.
That’s why the hunt is on to find the alternative treatment to save people’s lives till the vaccine arrives. And the antibody-based treatments offer an excellent hope. That’s what companies like Regeneron, Eli Lilly, Vir Biotechnology and many more from USA, Europe and Asia Pacific are working on antibodies for COVID-19.
Why antibodies?
Bu hikaye BioSpectrum Asia dergisinin July 2020 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin July 2020 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
